Bimatoprost

Catalog No.S1407

For research use only.

Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.

Bimatoprost Chemical Structure

CAS No. 155206-00-1

Selleck's Bimatoprost has been cited by 2 Publications

Purity & Quality Control

Choose Selective Prostaglandin Receptor Inhibitors

Biological Activity

Description Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
In vitro

Bimatoprost mildly stimulates the rate of aqueous humor flow during the day (13%) and at night (14%), its ocular hypotensive action is due primarily to a 26% reduction in the tonographic resistance to outflow. Bimatoprost enhances the pressure-sensitive outflow pathway. [1] Bimatoprost displaces [3H]prostaglandin F(2alpha) from FP receptors with K(i) of 6.31 μM. Bimatoprost rapidly mobilizes intracellular Ca(2+) via cloned human FP receptors expressed in human embryonic kidney cells and via native FP receptors in 3T3 mouse fibroblasts with EC(50) of 2.94 μM and 2.2 μM. [2] Bimatoprost up-regulates Cyr61 mRNA expression in the cat iris. Bimatoprost-induced up-regulation of Cyr61 mRNA expression is not because of the activation of the prostaglandin FP receptor but a different receptor. [3] Bimatoprost consistently evokes responses in different cells within the same tissue preparation, whereas prostaglandin F(2 alpha) and 17-phenyl prostaglandin F(2 alpha) elicites signaling responses in the same cells. Bimatoprost selectively stimulates intracellular calcium signaling in different cat iris sphincter cells. [4]

In vivo Bimatoprost is the ethyl amide derivative of 17-phenyl trinor PGF2α, a potent prostaglandin FP receptor agonist. Bimatoprost elicits an immediate, robust spike in [Ca2+] that rapidly decayes back to baseline levels. Bimatoprost possess direct agonist activities at the rat, mouse, and human FP prostanoid receptor. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 415.57
Formula

C25H37NO4

CAS No. 155206-00-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04647214 Recruiting -- Open-angle Glaucoma|Ocular Hypertension Allergan March 3 2021 --
NCT04285580 Completed Drug: Bimatoprost SR|Drug: LUMIGAN Open-Angle Glaucoma|Ocular Hypertension AbbVie June 11 2020 Phase 3
NCT03891446 Enrolling by invitation Drug: Bimatoprost SR|Other: Standard of Care Open-Angle Glaucoma|Ocular Hypertension AbbVie March 27 2019 Phase 3
NCT02676310 Terminated Drug: Bimatoprost Alopecia|Alopecia Androgenetic|Baldness Allergan March 2016 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Bimatoprost | Bimatoprost ic50 | Bimatoprost price | Bimatoprost cost | Bimatoprost solubility dmso | Bimatoprost purchase | Bimatoprost manufacturer | Bimatoprost research buy | Bimatoprost order | Bimatoprost mouse | Bimatoprost chemical structure | Bimatoprost mw | Bimatoprost molecular weight | Bimatoprost datasheet | Bimatoprost supplier | Bimatoprost in vitro | Bimatoprost cell line | Bimatoprost concentration | Bimatoprost nmr